Öйú°×ñ°·çЭ»áÁÙ´²¿ÆÑÐЭ×÷µ¥Î» ÖлªÖÐҽҩЭ»áÏȽø»áÔ±µ¥Î»
ר¼Ò
°×ñ°·çÕïÁÆר¼Ò£ºÍ¯Ñ§æ« Ö÷ÈÎҽʦ
×Éѯ
×Éѯ
°×ñ°·çר¼Ò£ºÌïÎÄ°Á ¸±Ö÷ÈÎҽʦ
×Éѯ
×Éѯ
°×ñ°·çÖÎÁÆר¼Ò£ºÁÖÓÀÏé Ö÷ÈÎҽʦ
×Éѯ
×Éѯ
°×ñ°·çÖÎÁÆר¼Ò£ºÎâÕ¼ÇÙ ¸±Ö÷ÈÎҽʦ
×Éѯ
×Éѯ
°×ñ°·çÖÎÁÆר¼Ò£ºÐÜÍòÖÚ ¸±Ö÷ÈÎҽʦ
×Éѯ
×Éѯ

¿µ¸´²¡Àý

¿µ¸´²¡Àý
½ÏºÃµÄ³ÉÈËÀñ¡ª¡ª¸æ±ð
½ÏºÃµÄ³ÉÈËÀñ¡ª¡ª¸æ±ð

¡¾»¼ÕßÏêÇé¡¿18ËêµÄÀһֱÊǸö¶®ÊµÄÑô¹âÄк¢£¬ÓÉÓÚ¼Ò ...²é¿´Ïêϸ>>

ÖØÊ°ÃÀÀö£¬Îҵİ×ñ°·ç
ÖØÊ°ÃÀÀö£¬Îҵİ×ñ°·ç

¡¾»¼ÕßÏêÇé¡¿ÔÀij£¬ËÄ´¨¹ãÔªÈË£¬29Ë꣬´½²¿Ï·½Óа×ñ°·ç ...²é¿´Ïêϸ>>

ÃÀÀö¼ÌÐø£¬°×ñ°·ç´Ó´Ë
ÃÀÀö¼ÌÐø£¬°×ñ°·ç´Ó´Ë

¡¾»¼ÕßÏêÇé¡¿À´×ÔËÄ´¨¹ãÔªµÄ°×ñ°·ç»¼ÕߺÎͬѧ£¬ÏÂò¢²¿°× ...²é¿´Ïêϸ>>

¸æ±ð°×ñ°·ç »¹Äãö¦Àö
¸æ±ð°×ñ°·ç »¹Äãö¦Àö

¡¾»¼ÕßÏêÇé¡¿»¼Õß3ÄêÇ°ÎÞÃ÷ÏÔÓÕÒò·¢ÏÖÒ¸ÏÂÒ»°×°ß£¬Öð½¥ ...²é¿´Ïêϸ>>

Îҵİ×ñ°·çÖκÃÁË£¬ÐÂ
Îҵİ×ñ°·çÖκÃÁË£¬ÐÂ

¡¾»¼ÕßÏêÇé¡¿ºúÏÈÉúÓÚ2010ÄêÏľ±²¿³¤³öС°×É«°ßµã£¬Æð³õ ...²é¿´Ïêϸ>>

Öκð×ñ°·ç »¼ÕßÖØ»ñ
Öκð×ñ°·ç »¼ÕßÖØ»ñ

¡¾»¼ÕßÏêÇé¡¿2ÄêÇ°»¼Õß·¢ÏÖ¾±²¿³öÏְװߣ¬Ôøµ½Æ¤Ñ×ËùÖÎ ...²é¿´Ïêϸ>>

Öκð×ñ°·ç»¼ÕßÁ³ÉÏÖØ
Öκð×ñ°·ç»¼ÕßÁ³ÉÏÖØ

¡¾»¼ÕßÏêÇé¡¿»¼Õß½ü°ëÄê¾±²¿°ßƬ״ɫËØÍÑʧ°ßÎÞÍÑм£¬Æ½ ...²é¿´Ïêϸ>>

лijij Å® 9Ëê
лijij Å® 9Ëê

¡¾»¼ÕßÏêÇé¡¿»¼Õß¼Ò³¤ÎÞÒâ¼ä·¢ÏÖ»¼Õ߸ØÃÅÖÜÓаװß×´£¬·¢ ...²é¿´Ïêϸ>>

ÂÞijij£¬12Ë꣬ÄÐ
ÂÞijij£¬12Ë꣬ÄÐ

¡¾»¼ÕßÏêÇé¡¿»¼ÕßÓҲྱ²¿³öÏÖ°×ñ°·çÖ¢×´ÒÑÓнü°ëÄêʱ¼ä ...²é¿´Ïêϸ>>

À´ÔºÂ·Ïß
  • ¼²²¡×Ô²â
  • ÖÎÁÆ·½°¸
  • ×Éѯר¼Ò
  • ר¼Ò´ðÒÉ
  • ԤԼר¼Ò
  • ר¼ÒQQ
  • ³Ë³µÂ·Ïß

°×ñ°·ç¹âÁÆÑо¿½øÕ¹

À´Ô´£º³É¶¼°×ñ°·çҽѧÑо¿Ôº¸½ÊôÒ½Ôº ·¢²¼Ê±¼ä£º2013-02-05 µã»÷´ÎÊý£º4762

¡¾ÕªÒª¡¿  °×ñ°·çÊÇÒ»ÖÖÉ«ËØÍÑʧÐÔ¼²²¡¡£¶ø¹âÁÆ×÷ΪÆäÖ÷ÒªÖÎÁÆ·½·¨Ö®Ò»±»¹ã·ºÔËÓᣱ¾ÎľͰüÀ¨¹â»¯Ñ§ÁÆ·¨£¬Õ­Æ×Öв¨×ÏÍâÏߣ¬308?nm×¼·Ö×Ó¹âµÈ¹âÁÆ·¨½üÄêÀ´µÄ·¢Õ¹×÷Ò»×ÛÊö¡£

¡¾¹Ø¼ü´Ê¡¿ °×ñ°·ç ¹â»¯Ñ§ÁÆ·¨ Õ­Æ×Öв¨×ÏÍâÏß 308 nm×¼·Ö×Ó¹â

ÖÚËùÖÜÖª£¬°×ñ°·çΪһɫËØÍÑʧÐÔ¼²²¡£¬ÑÏÖØÓ°Ïì×Å»¼ÕßÉíÐĽ¡¿µ£¬ÌرðÊDZ©Â¶²¿Î»µÄ»¼ÕßÒ»°ã¾ßÓгÁÖصľ«Éñ¸ºµ£¡£µ«Æù½ñΪֹ£¬ÒòÆä¾ßÌ岡ÒòÉв»ÍêÈ«Çå³þ£¬ÓÐÒ×Õï¶ÏÄÑÖÎÁƵÄÌص㣬Òò´Ë£¬Ä¿Ç°¶à²ÉÓÃ×ÛºÏÁÆ·¨£¨°üÀ¨ÊÖÊõ£¬Ò©Îï¼°ÎïÀíÖÎÁÆ£©¡£¶ø¹â»¯Ñ§ÁÆ·¨×÷ΪÎïÀíÖÎÁƵÄÖØÒª²¿·Ö£¬Îª´ó¼ÒËù¹Ø×¢£¬±¾ÎľͽüÄêÀ´°×ñ°·çµÄ¹âÁÆÑо¿½øÕ¹×÷Ò»×ÛÊö¡£

1 ¹â»¯Ñ§ÁÆ·¨
¹â»¯Ñ§ÁÆ·¨Êǽ«¹âÃô¼ÁºÍ³¤²¨×ÏÍâÏߣ¨320?480nmµÄ×ÏÍâÏߣ¬Ð¡²¿·Ö±»±íƤÎüÊÕ£¬´ó²¿·ÖÄÜ͸¹ý±íƤ´ïÕæƤ£¬ÉõÖÁÕæƤÖв¿£©½áºÏÖÎÁƼ²²¡µÄ·½·¨¡£Æä¿ÉÄÜ»úÖÆ£º´Ù½øºÚËØϸ°ûDNA¸´ÖÆ£¬Ê¹Ï¸°ûÓÐË¿·ÖÁÑÖÜÆÚËõ¶Ì£¬ºÚËØСÌåÊýÄ¿£¬ºÚËØϸ°ûÍ»Ôö¶à£¬ÀÒ°±Ëá±í´ïÔö¼Ó¼°Óй¦ÄܵĺÚËØϸ°ûÊýÁ¿Ôö¼Ó£¬Ä¿Ç°Ö÷ÒªÓÐÒÔϼ¸ÖÖ¡£

1.1 ²¹¹ÇÖ¬Ëع⻯ѧÁÆ·¨(PUVA) 8?¼×Ñõ²¹¹ÇÖ¬ËØ1948Äê¼´ÓÃÓÚÖÎÁÆ°×ñ°·ç£¬µ«×ÏÍâÏß¼Ó²¹¹ÇÖ¬ÖÎÁÆ°×ñ°·çÊÇÓÚ1974ÓÉParrishÊ×ÏÈÌá³ö£¬³õÊÇÓÃÓÚÖÎÁÆÒøм²¡£¬²»¾Ã¼´·¢ÏÖUVA¿ÉÒÔ¼¤»î8?¼×Ñõ²¹¹ÇÖ¬ËصĻîÐÔ£¬Ò»Ö±ÑØÓÃÓÚ½ñ¡£ÏÖ¶à²ÉÓõķ½·¨ÊÇ£Û1£Ý£º¶ÔÓÚ·º·¢ÐÔ°×ñ°·ç»ò¾Ö²¿ÖÎÁÆÎÞЧÕߣ¬ÖÎÁÆÇ°Ê×ÏÈ¿Ú·þ8?¼×Ñõ²¹¹ÇÖ¬ËØ£¨0.5¡«0.6mg/kg£©Á½Ð¡Ê± ºóÕÕUVA¡£ÖÎÁÆÇ°Ó¦Ê×ÏȲⶨС¹â¶¾Á¿£¨MPD)£¬Ê×´ÎÖÎÁÆÁ¿Ò»°ã1/2¡«3/4MPD£¬ÒÔºó¸ù¾ÝÇé¿öÿ¸ô1¡«2´ÎÔö¼Ó1/4¡«1/2MPD¡£¶ÔÓÚÖйúÈËƤ·ô£¬UVAµÄ³õ¼ÁÁ¿Í¨³£ÊÇ1¡«2J/cm2£¬Ã¿´ÎÔö¼Ó0.25¡«0.5J/cm2£¬Ö±µ½ºì°ß³öÏÖ£¬Ã¿ÖÜ2¡«3´Î£¬Ò»¸öÁƳ̿ɳ¤´ï30´Î»ò¸ü¶à¡£ÖÎÁÆÖд󲿷ÖƤËðÏûÍË»òÃ÷ÏÔºÃתʱ¸ÄÓÃά³ÖÁ¿£¬¼´1¡«2ÖÜÕÕÉä1´Î¡£¶ø¶ÔÓÚƤËð·¶Î§Ð¡£¬ÊýÄ¿ÉÙÕߣ¬¿ÉÓÚƤËð´¦Í¿0.2%µÄ8?¼×Ñõ²¹¹ÇÖ¬ôú£¬0.5Сʱºó¹âÕÕ¡£ÉÏÊöÖÎÁÆʱ¾ùÓ¦´÷»¤Ä¿¾µ±£»¤Õý³£Æ¤·ô£¬ÒÔ¾¡¿ÉÄܵļõÉٹⶾ·´Ó¦¡£½üÀ´ÓÐÈËÌá³öÓÃ5?¼×Ñõ²¹¹ÇÖ¬ËØ´úÌæ8?¼×Ñõ²¹¹ÇÖ¬ËØ£¬¹â¶¾¸±×÷ÓøüС¡£ µ« PUVAÓÐ×Ų»ÊÊÓÚ12ËêÒÔϵĶùͯӦÓ㬾ßÓйⶾÐÔ£¬Ò×ÖÂƤ·ôÀÏ»¯£¬°×ÄÚÕϼ°ÓÕ·¢Æ¤·ôÖ×ÁöµÈÌص㡣

1.2 ¿­ßø¹â»¯Ñ§ÁÆ·¨(KUVA) ¿­ßøÊÇÒ»ÖÖ߻૲¢É«Í­£¬Æ仯ѧ½á¹¹¼°ÉúÎï»îÐÔ¾ùÀàͬÓÚ²¹¹ÇÖ¬£¬µ«¶¾ÐÔÏà¶ÔС£¬°²È«ÐԺöø»¼ÕßÒÀ´ÓÐԸߣÛ2£Ý¡£Hofer A µÈÑ¡È¡ÁË28Àý·º·¢ÐÔ°×ñ°·ç»¼Õߣ¨ÄÐ13Ãû£¬Å®15Ãû£»Æ½¾ù15¡«51Ë꣬ƽ¾ù34Ë꣩£¬¾ùÔÚ14ÄêµÄij¶Îʱ¼ä½ÓÊÜÁ˳¬¹ý6¸öÔµÄKUVAµÄÖÎÁÆ£¬Í¨¹ýÖÎÁÆÇ°ºóͼƬ¶Ô±ÈÖÎÁÆÇ°ºóƤËðÇøÉ«Ëػָ´Çé¿ö½øÐÐÏà¹Ø·ÖÎö·¢ÏÖÊǾßÓÐͳ¼ÆѧÒâÒåµÄ£¬ÁÆЧͬÖÎÁÆ´ÎÊý£¨r=0.833£¬£Ð=0.001£©£¬Í¬UVAµÄÀÛ»ý¼ÁÁ¿£¨r=0£¬840£¬£Ð=0.001£©¶¼ÓÐÏà¹ØÐÔ¡£ÔÚ³ÖÐøÖÎÁÆʱ¼ä³¬¹ý3¸öÔµIJ¡ÈËÖУ¬Æ½¾ùÖÎÁÆ´ÎÊý´Î194(69¡«386)£¬Æ½¾ùµÄUVAÀÛ»ý¼ÁÁ¿2.036J/cm2(690¡«4411J/cm2)£¬ 41%µÄ»¼ÕßЧ¹ûºÃ£¨ÈçƤËð´¦70%µÄÉ«Ëصõ½Á˻ָ´¡£³£¼ûµÄ¶ÌÆÚ¸±×÷ÓÃÊÇÇá΢µÄ¶ñÐÄ£¬28¸ö»¼Õß¹²ÓÐ8¸ö³öÏÖ£¬¶øÇÒÖ÷ÒªÔÚÖÎÁƵijõ¼¸¸öÖܳöÏÖ£»ÔÚKUVAÖÎÁƽáÊøºó³¤´ï4¡«110¸öÔ£¨Æ½¾ù40¸öÔ£©µÄËæ·ÃÆÚÄÚ£¬28ÈËÖÐÄÜËæ·Ãµ½µÄ23È˾ùûÓгöÏÖƤ·ô°©ºÍ¹â»¯ÐÔƤ·ô²¡£¬½á¹û³ä·ÖÖ¤Ã÷KUVAÖÎÁÆ°×ñ°·ç,¼ÙÈçÖÎÁÆʱ¼ä×ã¹»£¬²»½öÊÇÓÐЧµÄÒ²ÊÇ°²È«µÄ¡£Clrlie G µÈÈË£Û3£Ýͨ¹ýÌåÍâʵÑé²ûÃ÷KUVAµÄÖÎÁÆ»úÖÆ£º±»UVA¼¤»îµÄ¿­ßø´Ì¼¤Á˺ÚËØϸ°ûµÄÔöÖ³ºÍºÚÉ«ËصÄÉú³É¡£Valkovas £Û4£Ý¹Û²ìµ½É«Ëػָ´Í¬ÄêÁäÓн̴óµÄÏà¹ØÐÔ£¨É«Ëػָ´ÂÊ=81.76?(1.48*»¼ÕßÄêÁä)¡£

1.3 ±½±û°±Ëá¹â»¯Ñ§ÁÆ·¨ ±½±û°±ËáÁªºÏUVAÖÎÁÆ°×ñ°·ç1983Äê¼´ÓÃÓÚÁÙ´²£¬ÏÖ¶à²ÉÓñ½±û°±ËáµÄÇ°Ìå×óÐý±½±û°±ËᣬËüÄÜÔÚÀÒ°±ËáøµÄ×÷ÓÃϺϳɺÚÉ«ËØ¡£´Ë·¨ÓÅÓÚÆäËüÁÆ·¨ÔÚÓÚËüÄÜÌá¸ß°×°ßÇøƤ·ô¶Ô¹âµÄÄÍÊÜÐÔ¡£KniterµÈÔø¶Ô21Àý»¼ÕßÓ¦ÓÃ×óÐý±½±û°±Ëá¼ÓUVAÖÎÁÆ°×ñ°·ç£¬×ÜÓÐЧÂÊ´ïµ½ÁË85%´ËÁÆ·¨¸üÄÜÌá¸ß°×°ßÇøƤ·ô¶Ô¹âµÄÄÍÊÜÐÔ£¬ÔÚ¹úÍâÒÑÍƹãÓ¦Óá£

1.4 ¿¨²´Èý´¼¹â»¯Ñ§ÁÆ·¨£Û5£Ý ºÚËØϸ°û±íÃæ±í´ïάÉúËØD3ÊÜÌ壬1£¬25¶þôÇάÉúËØD3¿Éµ÷½ÚºÚËغϳɣ¬¿¨²´Èý´¼ÏµÎ¬ÉúËØD3 1£¬25(OH)2D3»îÐÔ´úлÎïµÄÀàËÆÎËü¿ÉÄÜͨ¹ýºÚÉ«ËØϸ°ûÉϵÄάÉúËØD3ÊÜÌå»òµ÷½Úϸ°ûÄÚ¸ÆÎÉÂÒ¶ø·¢»Ó×÷ÓãÛ6£Ý¡£2001ÄêErimsµÈÈËÑ¡È¡35ÀýÑ°³£ÐÍ°×ñ°·ç»¼Õߣ¬²ÉÓÃËæ»ú˫ä¶ÔÕÕʵÑ飬Ñо¿½á¹ûÏÔʾ¿¨²´Èý´¼¹â»¯Ñ§ÁÆЧ¹ûÁ¼ºÃ¡£

2 Õ­Æ×Öв¨×ÏÍâÏߣ¨NB?UVB£©
1997ÄêWesterhof£Û7£ÝÂÊÏÈÓÃÓÚ°×ñ°·çµÄÖÎÁÆ£¬2001ÄêScherschem L£Û8£Ý ÔÙ´Îͨ¹ýÊÔÑé¿Ï¶¨ÆäÁÆЧ¡£2007ÄêYonessµÈ£Û9£ÝÑ¡È¡ÁË65Ãû·Ç½Ú¶ÎÐÔ°×ñ°·çµÄ»¼Õߣ¬²ÉÓÃ˫äËæ»ú¶ÔÕÕÊÔÑ飬ÖÎÁÆ12¸öÔºó¹Û²ìÆäÁÆЧ£¬½á¹û·¢ÏÖÔڷǽڶÎÐÔ°×ñ°·ç»¼ÕßÖУ¬NB?UVBÓÅÓÚÆÕͨµÄPUVA¡£Ä¿Ç°ÆÕ±éÈÏΪNB?UVBÊÊÓÚ·º·¢ÐÔ°×ñ°·çµÄÈ«ÉíÖÎÁÆ£¬ÁÆЧÓëÀÛ»ýÕÕÉä´ÎÊýÃÜÇÐÏà¹Ø£¬ÕÕÉä´ÎÊýÒÔÿÖÜ1?2´ÎΪÒË£¬Ò»°ã1Ôºó²ÅÄÜÏÔЧ£¬ÁƳÌÐè°ëÄêÒÔÉÏ¡£NijooµÈ£Û10£Ý»¹Ó¦ÓÃ311nm NB?UVBÖÎÁÆ51Àý·º·¢ÐÔ°×ñ°·ç»¼¶ù£¬¹Û²ì½á¹ûÈÏΪNB?UVB ÖÎÁƶùͯ°×ñ°·çÒ²ÊÇÓÐЧµÄºÍ°²È«µÄ£¬¿ÉÒÔÃ÷ÏÔÌá¸ßÉú»îÖÊÁ¿¡£

3 308?nm×¼·Ö×Ó¹â
308?nm×¼·Ö×ӹ⼴ÂÈ»¯ë¯×¼·Ö×ӹ⣬ÊÇÒ»ÖÖÐÂÐ͵ÄÒ½Óù⣬Æ䲨³¤ÔÚUVB·¶Î§ÄÚ¡£308?nm×¼·Ö×Ó¹âÉî¿ÉÖÁ1.5nmµÄÕæƤdz²ã£¬ÇÒÖ»Õë¶ÔƤËð²¿Î»£¬Òò´Ë¶ø¾ßÓиßÑ¡ÔñÐÔ¡££Û11£ÝNovakͨ¹ýÑо¿ÏÔʾÆä×÷ÓûúÖÆÖ÷ÒªÓëÆä¿É´Ùʹ°×ñ°·çƤËðÄڻµÄTϸ°ûµòÍöÓйء£2002ÄêÃÀ¹úSpencerÊ״ᨵÀÔËÓÃËüÖÎÁÆ°×ñ°·çµÄ½á¹û£¬¹úÄÚ2005ÄêÑî»ÛÀ¼µÈ£Û12£Ý¹Û²ìÁ˽ü500Àý¸÷ÐÍ°×ñ°·çµÄ»¼Õߣ¬Í¨³£308?nm×¼·Ö×Ó¹â5¡«6´Î£¬Ô­ÓеÄÍêÈ«ÐÔ°×°ßÉÏ¿ªÊ¼³öÏÖµã×´µÄÉ«Ëصº£¬¾­¹ýÿÖÜ2´Î¹²10ÖܵÄÖÎÁÆ£¬10%¡«15%µÄ»¼Õß¿ÉÍêÈ«¸´É«£¬ÏÔЧÂÊ¿É´ï50%×óÓÒ£¬ÓÐЧÂÊÔò´ï90%ÒÔÉÏ£Û13£Ý¡£Passeron T µÈÈËҲͨ¹ýÑо¿Ö¤Êµ£º308?nm×¼·Ö×Ó¹âÖÎÁƾÖÏÞÐÔ°×ñ°·çµÄÓÐЧÐԺͰ²È«ÐÔ¶¼Êǿ϶¨µÄ£¬µ«ÊÇÔËÓÃÓÚ×ÏÍâÏßÃô¸ÐÇøÓò£¨ÈçÃ棬¾±£¬Çû¸ÉµÈ²¿Î»£©Ð§¹û¸üΪÏÔÖø¡£¾ÝÏÖÓеÄÎÄÏ×£¬ÎÒÃÇÈÏΪ308?nm×¼·Ö×Ó¹âµÄÖ÷ÒªÊÊÓ¦Ö¢»¹ÊǾ²Ö¹ÆÚ°×ñ°·ç»¼Õߣ¬ÓÈÆäÊÇÃæ»ýСµÄ»¼Õß¡£ÆäÖ÷Òª¸±×÷ÓÃÊÇÖÎÁƲ¿Î»µÄºì°ß£¬Í¬Ê±Ò²¿ÉÒÔ³öÏÖË®ð壬´ÌÍ´²»ÊÊ£¬ÒÔ¼°µ¼ÖÂƤ·ôÖ×ÁöµÈ£Û14£Ý£¬µ«Æäµ¼ÖÂÖ×ÁöµÄΣÏÕÐÔËæ×ÅÀÛ»ýÕÕÉä¼ÁÁ¿µÄÔö¼Ó¶øÔö¼Ó£¬¶ø308?nm×¼·Ö×Ó¹âÖÎÁÆ°×ñ°·çµÄÀÛ»ýÕÕÉäÁ¿Ô¶µÍÓÚNB?UVB¡£Òò´Ë£¬ÔÚÁÙ´²É϶à´Î±»Ö¤Ã÷¾ßÓбÈPUVAºÍNB?UVB¸üºÃµÄÁÆЧ£¬É«ËØ¿ìËÙÔÙÉúÇÒά³Öʱ¼ä³¤¾Ã¡£

4 ÁªºÏÖÎÁÆ¡¡
Passeron T£Û13£ÝµÈÈËÑ¡È¡14Ãû»¼ÕßÓÃ0.1%Ëû¿ËĪ˾Èí¸àÁªºÏ308?nm×¼·Ö×ӹ⣬½á¹ûÏÔʾ¶þÕßÁªºÏÁÆЧÓÅÓÚÁ½Õ߸÷×Ôµ¥¶ÀʹÓÃ308?nm×¼·Ö×Ó¹âͬ¿¨²´Èý´¼ÁªºÏÖÎÁÆÒ²ÓкõÄÁÆЧ¡£¡£Ostovari N£Û15£ÝµÈÈ˱¨µÀËû¿ËĪ˾ÔÚûÓÐUVBµÄÇé¿öÏÂÖÎÁÆ°×ñ°·çÊÇȱ·¦ÓÐЧÐԵġ£Mehrabi D£Û16£Ý ͨ¹ýËæ»ú£¬Ë«Ã¤£¬°²Î¿¼Á¶ÔÕÕ±ÈÑо¿·¢ÏÖÔÚ·º·¢ÐÔ°×ñ°·çµÄÖÎÁÆÖУ¬Ëû¿ËĪ˾ÁªºÏNB?UVBÊÇÓÅÓÚµ¥¶ÀʹÓÃNB?UVBµÄ£¬½øÒ»²½ËµÃ÷ÁËÁ½Õß¾ßÓÐЭͬ×÷ÓãÛ16£Ý¡£NB?UVBͬ¿¨²´Èý´¼£¬¼¤ËØÀàÈí¸àÈç£Û17£Ý·ú¿¨ÌæËáͬUVA½áºÏʹÓõÄЭͬЧӦ£¬Ò඼Óб¨µÀ¡£²»½öÈç´Ë£¬¶ÔÓÚÐбíƤϸ°ûÒÆÖ²µÄ°×ñ°·ç»¼Õߣ¬UVAÄÜÔö¼ÓÆäÖÎÓúÂÊ£Û18£Ý¡£ÓÐÑо¿ÏÔʾ°×ñ°·ç»¼ÕßѪҺÖÐÒ¶ËáºÍ΢ÉúËØB12ˮƽµÍÓÚ³£ÈË¡£Julin£Û19£ÝµÈÑ¡È¡100Àý°×ñ°·ç»¼Õߣ¬¸øÒÔ¿Ú·þÒ¶ËáºÍάÉúËØB12£¬ÏÄÌìÕÕÉäÈչ⣬¶¬ÌìÕÕÉäUVB£¬ÖÎÁÆʱ¼äÖÁÉÙ´óÓÚ3¡«6Ô£¬½á¹û±íÃ÷52ÀýÓÐÃ÷ÏÔЧ¹û£¬±©¹â²¿Î»É«Ëػָ´Ã÷ÏÔ£¬38%»¼Õ߻ָ´Ã÷ÏÔµÄʱ¼äÊÇÏļ¾¡£µ«Ðè½øÒ»²½Ñо¿Ã÷ȷάÉúËؼ°¹âÕÕµÄС¼ÁÁ¿¼°ÁƳ̡£

¶ø¹úÄÚ¸ü¶àµÄ±¨µÀÊÇNB?UVBÓëÌÇƤÖʼ¤ËØÈí¸à£¨ÈçËû¿¨Î÷´¼£¬Â±ÃÀËÉ£©£»ÓëÃâÒßÒÖÖƼÁ£¨ÈçËû¿ËĪ˾£©£¬¹âÁÆͬÖÐÒ©ÖƼÁ£¨È縴·½¿¨Á¦×ÎÈ»ôú£©£¬ÒÔ¼°ÖвÝÒ©£¬Õë¾ÄµÈ×æ¹úҽѧÁªºÏÖÎÁƾùÈ¡µÃÁËÒ»¶¨µÄÁÆЧ¡£

Ëæ×ÅҽѧÊÂÒµÈÕÐÂÔÂÒìµÄ·¢Õ¹£¬ÒÔ¼°¶ÔÓÚ°×ñ°·çÑо¿µÄ½øÒ»²½ÉîÈ룬ÎÒÃÇÏàÐŹâÁÆÒ»¶¨ÄܸüºÃµÄÓÃÓÚ°×ñ°·çµÄÖÎÁÆ¡£


¡¾²Î¿¼ÎÄÏס¿

£Û1£Ý Mc Nedy W£¬Goa KL. 5?Methoxypsoralen A review of its effects in psoriasis and vitiligo£ÛJ£Ý. Drugs£¬1998£¬56(4):667¡«690.

£Û2£Ý Hofer A£¬Kerl H£¬Holf P. Long?term results in the treatment of vitiligo with oral khellin plus UVA£ÛJ£Ý. Eur J Dematol.2001 May?June;11(3):225¡«229.

£Û3£Ý Carlie G£¬ Ntusi NB£¬Hulley PA£¬Kidson SH. KUVA stimulates proliferation and melanogenesis in normal human melanocytes and melanoma cells in vitro£ÛJ£Ý. Br J Dermatol.2003 oct£¬149(4):707¡«717.

£Û4£Ý Valkova S£¬Trashlieva M£¬ Christova P. Treament of vitiligo with local khellin and UVA£¬comparison with systemic PUVA£ÛJ£Ý.Clin Exp Dematol.2004 May£¬29(2):180¡«184.

£Û5£Ý Schallreuter KU£¬Moore J£¬Behrens?Williams s. Rapid initiation of repigmentation in vitiligo with Dead sea climatotherapy in combination with pseudocatalase (pc?ku)£ÛJ£Ý.In J Dtrmatol 2002£¬41(8):482¡«487.

£Û6£Ý Ermis O£¬ A lpsoy E£¬Cetin L£¬et al.Is the efficacy of psoralen plus ultraviolet A the rapy for vitiligo enhanced by concurrent topical calcipotriol£ÛJ£Ý£¬Br J Dermatol£¬2001£¬11(3):225¡«229£®

£Û7£Ý Westerhof W£¬Nieuweboer?Kroboreova L. Teatment of vitiligo with UV?B radiation vs topical psoralen plus UVA£ÛJ£Ý. Arch Dermatol£¬1997£¬33:1525¡«1528.

£Û8£Ý Scherschun L£¬Kim JJ£¬ Lim HW. Narrow band ultrabiolet B is a userul and well tolerated treatment for bitiligo£ÛJ£Ý.J Am Acad Dermatol£¬2001£¬44:999¡«1003.

£Û9£Ý Yoness ss. Palmer RA. Garibaldinos TM.HAWKJL Randomized double?blind trial of treatment of vitiligo :efficacy of psoralen?uv?A therapy vs Narrowband?uv?B therapy£ÛJ£Ý. Arch.Dermatol£¬2007 May£¬Jul£¬143(7):906.

£Û10£ÝNjoo MD£¬Bos JD£¬Westerhof W. Trenment of generalized vitiligo in children with narrow?band radiation therapy£ÛJ£Ý. J Am Acad Dermatol£¬2000£¬42(2 pt 1):245¡«253.

£Û11£ÝNovak Z£¬Bonis B£¬Baltas E£¬et al.Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow?band ultraviolet B£ÛJ£Ý. Photochem Photohiol B£¬2002£¬67(1):32¡«38.

£Û12£ÝÑî»ÛÀ¼£¬ÁõÖÙÈÙ£¬ÎâÑàºìµÈ.°×ñ°·çµÄ¹âÁÆ·¨£ÛJ£Ý.ÖйúÃÀÈÝҽѧ£¬ 2006£¬8£¬15£¨8£©£º977.

£Û13£ÝPasseron T£¬Ostovari n£¬Zakaria W£¬Fontas E£¬et al. Topical tacrolimus and the 308?nm excimer laser:a synergistic combination for the treatment of vitiligo.

£Û14£ÝÀîãüÜ°£¬¸ßÌìÎÄ.308?nm×¼·Ö×Ó¹âÖÎÁÆ°×ñ°·ç½øÕ¹£ÛJ£Ý.ÖйúƤ·ôÐÔ²¡Ñ§ÔÓÖ¾£¬2006£¬8£¬20£¨8£©.

£Û15£ÝOstovari N£¬Passeron T£¬Lacour JP£¬Ortonne JP. Lack of efficacy of tacrolimus in the treatment of vitiligo in the abensce of UV?B exposure£ÛJ£Ý. Arch Dermatol£¬2006 Feb£¬142(2):252¡«253£®

£Û16£ÝMehrabi D Pandya AG.A randomized£¬placebo?controlled£¬double?blind trial comparing narrowband UV?B plus 0.1% tacrolimus ointment with narrowband UV?B plus placebo in the treatment of generalized vitiligo.

£Û17£ÝDogra S.Parsad D. Combination of narrowband UV?B and topical calcipotriene in vitiligo£ÛJ£Ý. Arch Dermatol.2003 Mar£¬139(3):393.

£Û18£ÝAwad ss. Abdel?Raof H. Hosam EI?Din W.EI?Domyatim. Epithelial grafting for vitiligo requires ultraviolet A phototherapy to increase success rate£ÛJ£Ý. J Cosmet Dermatol.2007 Jun£¬6(2):119¡«124.

£Û19£ÝJuhlin L,Olsson MJ. Improvement of vitiligo after oral treatment with vitaminB12 and folic acid and the importance of sun exposure£ÛJ£Ý.Acta Dermvenerol.1997 NOV£¬77(6):460¡«462.


  • Ò½ÔºÈÙÓþ
  • ÏȽøÉ豸
  • Ò½Ôº»·¾³
  • ºÏ×÷»ú¹¹
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • Ò½ÔºÈÙÓþ
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • ÏȽøÉ豸
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³
  • Ò½Ôº»·¾³